{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:45Z","timestamp":1793948445330,"version":"4.8.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41431-024-01769-7","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T10:58:23Z","timestamp":1734260303000},"page":"413-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas"],"prefix":"10.1038","volume":"33","author":[{"given":"David F. G. J.","family":"Wolthuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7476-6867","authenticated-orcid":false,"given":"Marga","family":"Nijenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Soree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke J.","family":"de Boer-Veger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Buunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Risselada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard A. P. J. M.","family":"Rongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3965-5552","authenticated-orcid":false,"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"van Westrhenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera H. M.","family":"Deneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9927-7266","authenticated-orcid":false,"given":"Elisa J. F.","family":"Houwink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1371\/journal.pmed.0040209","volume":"4","author":"JJ Swen","year":"2007","unstructured":"Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 2007;4:e209.","journal-title":"PLoS Med"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharm Ther. 2011;89:662\u201373.","journal-title":"Clin Pharm Ther"},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/cpt.1049","volume":"103","author":"JJ Swen","year":"2018","unstructured":"Swen JJ, Nijenhuis M, van Rhenen M, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Pharmacogenetic information in clinical guidelines: the European perspective. Clin Pharm Ther. 2018;103:795\u2013801.","journal-title":"Clin Pharm Ther"},{"key":"1769_CR4","unstructured":"European Association for Clinical Pharmacology and Therapeutics (EACPT). Available from: https:\/\/www.eacpt.eu\/."},{"key":"1769_CR5","unstructured":"European Association of Hospital Pharmacists (EAHP). Available from: https:\/\/www.eahp.eu\/."},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","volume":"22","author":"P Vinci","year":"2021","unstructured":"Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22:11687.","journal-title":"Int J Mol Sci"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.33549\/physiolres.932865","volume":"63","author":"M Vrablik","year":"2014","unstructured":"Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res. 2014;63:S327\u201334.","journal-title":"Physiol Res"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/clpt.2014.121","volume":"96","author":"A Alfirevic","year":"2014","unstructured":"Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharm Ther. 2014;96:470\u20136.","journal-title":"Clin Pharm Ther"},{"key":"1769_CR9","unstructured":"National Center for Biotechnology Information (NCBI). SLCO1B1 solute carrier organic anion transporter family member 1B1 [Homo sapiens (human)]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/gene\/10599."},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.110.002857","volume":"63","author":"M Niemi","year":"2011","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharm Rev. 2011;63:157\u201381.","journal-title":"Pharm Rev"},{"key":"1769_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2009.54","volume":"10","author":"SP Romaine","year":"2010","unstructured":"Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2010;10:1\u201311.","journal-title":"Pharmacogenomics J"},{"key":"1769_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41431-024-01572-4","volume":"32","author":"LEN Manson","year":"2024","unstructured":"Manson LEN, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Houwink EJF, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs. Eur J Hum Genet. 2024;32:903\u201311.","journal-title":"Eur J Hum Genet"},{"key":"1769_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.clpt.6100507","volume":"83","author":"JJ Swen","year":"2008","unstructured":"Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharm Ther. 2008;83:781\u20137.","journal-title":"Clin Pharm Ther"},{"key":"1769_CR14","unstructured":"Royal Dutch Pharmacists Association (KNMP). Pharmacogenetic Recommendation Text. Available from: https:\/\/www.knmp.nl\/."},{"key":"1769_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","volume":"21","author":"K Karamperis","year":"2021","unstructured":"Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21:533\u201341.","journal-title":"Pharmacogenomics J"},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fphar.2019.00830","volume":"10","author":"S Simeonidis","year":"2019","unstructured":"Simeonidis S, Koutsilieri S, Vozikis A, Cooper DN, Mitropoulou C, Patrinos GP. Application of economic evaluation to assess feasibility for reimbursement of genomic testing as part of personalized medicine interventions. Front Pharm. 2019;10:830.","journal-title":"Front Pharm"},{"key":"1769_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cpt.762","volume":"103","author":"PCD Bank","year":"2018","unstructured":"Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, et al. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the Dutch pharmacogenetics working group. Clin Pharm Ther. 2018;103:599\u2013618.","journal-title":"Clin Pharm Ther"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharm Ther. 2022;111:1007\u201321.","journal-title":"Clin Pharm Ther"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01769-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:20:20Z","timestamp":1744273220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-024-01769-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1038\/s41431-024-01769-7","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,15]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Pharmacogenetics Working Group of the KNMP (DPWG) formulates the optimal recommendations for each phenotype group based on the available evidence. If this optimal recommendation cannot be followed due to practical restrictions, e.g. therapeutic drug monitoring or a lower dose is not available, then the health care professional should consider the next best option.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}